Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma DOI Creative Commons
Michael B. Atkins, Nizar M. Tannir

Cancer Treatment Reviews, Journal Year: 2018, Volume and Issue: 70, P. 127 - 137

Published: July 20, 2018

There has been significant progress in the treatment of patients with advanced clear cell renal carcinoma (ccRCC), improved knowledge disease biology and introduction targeted agents immunotherapies. In this review, we discuss current emerging first-line options, including recent approvals tyrosine kinase inhibitor (TKI) cabozantinib immunotherapy combination nivolumab (anti-programmed death 1 [PD-1])/ipilimumab (anti-cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]), initial outcomes atezolizumab (anti-PD-ligand [PD-L1])/bevacizumab (anti-vascular endothelial growth factor [VEGF]). Key clinical data are reviewed, as these novel treatments offer improvement, particularly for classified intermediate/poor risk whom previously available therapies have demonstrated limited efficacy. Treatment recommendations based on evidence expert opinion discussed. We also review ongoing studies investigating combinations checkpoint inhibitors TKIs, axitinib, other immunomodulatory agents, potential role single-agent select patients. With a growing armamentarium, identification validation biomarkers will be crucial optimizing selection sequences.

Language: Английский

Genomic correlates of response to immune checkpoint blockade DOI
Tanya E. Keenan, Kelly P. Burke, Eliezer M. Van Allen

et al.

Nature Medicine, Journal Year: 2019, Volume and Issue: 25(3), P. 389 - 402

Published: March 1, 2019

Language: Английский

Citations

415
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors DOI Creative Commons
Rilan Bai, Zheng Lv, Dongsheng Xu

et al.

Biomarker Research, Journal Year: 2020, Volume and Issue: 8(1)

Published: Aug. 26, 2020

Abstract Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has ushered in a new era anti-tumor therapy, with sustained responses and significant survival advantages observed multiple tumors, most patients do not benefit. Therefore, more attention been paid to identification predictive biomarkers for response ICIs, in-depth comprehensive understanding continuously explored recent years. Predictive markers ICIs efficacy have gradually from expression intermolecular interactions within tumor cells various molecules microenvironment, extended exploration circulating host systemic markers. With high-throughput sequencing microarray technology, variety biomarker strategies deeply achieved process single marker multifactorial synergistic Comprehensive predictive-models developed by integrating different types data based on components tumor-host is direction future research will profound impact field precision immuno-oncology. In this review, we analyze course progress as an adjunctive tool immunotherapy effectively identifying discuss their directions achieving

Language: Английский

Citations

389
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives DOI
Evgeny N. Imyanitov, Aglaya G. Iyevleva, E. Levchenko

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2020, Volume and Issue: 157, P. 103194 - 103194

Published: Dec. 11, 2020

Language: Английский

Citations

380
T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection DOI Open Access
Jonathan Trujillo, Randy F. Sweis, Riyue Bao

et al.

Cancer Immunology Research, Journal Year: 2018, Volume and Issue: 6(9), P. 990 - 1000

Published: Sept. 1, 2018

Immunotherapies such as checkpoint-blocking antibodies and adoptive cell transfer are emerging treatments for a growing number of cancers. Despite clinical activity immunotherapies across range cancer types, the majority patients fail to respond these resistance mechanisms remain incompletely defined. Responses immunotherapy preferentially occur in tumors with preexisting antitumor T-cell response that can most robustly be measured via expression dendritic CD8

Language: Английский

Citations

343
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma DOI Creative Commons
Michael B. Atkins, Nizar M. Tannir

Cancer Treatment Reviews, Journal Year: 2018, Volume and Issue: 70, P. 127 - 137

Published: July 20, 2018

There has been significant progress in the treatment of patients with advanced clear cell renal carcinoma (ccRCC), improved knowledge disease biology and introduction targeted agents immunotherapies. In this review, we discuss current emerging first-line options, including recent approvals tyrosine kinase inhibitor (TKI) cabozantinib immunotherapy combination nivolumab (anti-programmed death 1 [PD-1])/ipilimumab (anti-cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]), initial outcomes atezolizumab (anti-PD-ligand [PD-L1])/bevacizumab (anti-vascular endothelial growth factor [VEGF]). Key clinical data are reviewed, as these novel treatments offer improvement, particularly for classified intermediate/poor risk whom previously available therapies have demonstrated limited efficacy. Treatment recommendations based on evidence expert opinion discussed. We also review ongoing studies investigating combinations checkpoint inhibitors TKIs, axitinib, other immunomodulatory agents, potential role single-agent select patients. With a growing armamentarium, identification validation biomarkers will be crucial optimizing selection sequences.

Language: Английский

Citations

337